Active-not recruiting

This is a Phase 2 trial studying anti-CSF1R antibody in patients with ctDNA positive colorectal cancer minimal residual disease after completion of standard therapies.

This is a single arm Phase II cohort of RO7198457 in patients with circulating tumor DNA (ctDNA) positive surgically resected Stage IV CRC after standard of care adjuvant therapy. The study will test whether the vaccine can reduce recurrence of the cancer.

This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal or colon. The study will test whether the vaccine can reduce recurrence of the cancer.